Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.
复制标题
DOI：
10.1126/sciimmunol.abo2202
复制
发表时间：
2022-03-25
影响因子：
24.8
通讯作者：
de Vries RD
中科院分区：
文献类型：
--
作者：
GeurtsvanKessel CH;Geers D;Schmitz KS;Mykytyn AZ;Lamers MM;Bogers S;Scherbeijn S;Gommers L;Sablerolles RSG;Nieuwkoop NN;Rijsbergen LC;van Dijk LLA;de Wilde J;Alblas K;Breugem TI;Rijnders BJA;de Jager H;Weiskopf D;van der Kuy PHM;Sette A;Koopmans MPG;Grifoni A;Haagmans BL;de Vries RD
严重急性呼吸窘迫综合征冠状病毒2型（SARS-CoV-2）Omicron变异体（B.1.1.529）正在迅速传播，即使在接种疫苗的个体中也是如此，这引起了人们对免疫逃逸的担忧。在这里，我们研究了在用ChAdOx-1 S、Ad26.COV2.S、mRNA-1273或BNT 162 b2免疫接种后，针对SARS-CoV-2 D 614 G（野生型，WT）和B.1.351（Beta）、B.1.617.2（Delta）和B.1.1.529（Omicron）相关变体（VOC）的中和抗体和T细胞应答。在用两种mRNA疫苗（mRNA-1273或BNT 162 b2）接种后28天检测到针对WT SARS-CoV-2刺突（S）的高结合抗体水平，其在6个月后显著降低。相比之下，Ad26.COV2.S疫苗接种后抗体水平较低，但并未减弱。感染性病毒的中和试验显示，β和δ变体具有一致的交叉中和作用，但Omicron的中和作用显著降低或不存在（与WT相比降低高达34倍）。值得注意的是，在两次mRNA-1273免疫或Ad26.COV.2引发后的BNT 162 b2加强免疫接种部分恢复了Omicron变体的中和，但与WT相比，应答仍降低高达17倍。在所有疫苗接种方案后6个月内检测到SARS-CoV-2特异性T细胞，特异性CD 4 + T细胞的检测比CD 8 + T细胞更一致。WT和变体特异性CD 4+或CD 8 + T细胞应答（包括Omicron）之间未检测到显著差异，表明T细胞水平的逃逸最小。这项研究表明，接种疫苗的个体保留了对SARS-CoV-2 Omicron变体的T细胞免疫力，可能平衡了预防或限制严重COVID-19的中和抗体缺乏。需要加强疫苗接种以进一步恢复抗体的Omicron交叉中和。疫苗诱导的SARS-CoV-2特异性CD 4+和CD 8 + T细胞靶向祖先刺突蛋白交叉识别Omicron变体。
The severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) Omicron variant (B.1.1.529) is spreading rapidly, even in vaccinated individuals, raising concerns about immune escape. Here, we studied neutralizing antibodies and T-cell responses targeting SARS-CoV-2 D614G (wildtype, WT), and the B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants of concern (VOC) in a cohort of 60 health care workers after immunization with ChAdOx-1 S, Ad26.COV2.S, mRNA-1273 or BNT162b2. High binding antibody levels against WT SARS-CoV-2 spike (S) were detected 28 days after vaccination with both mRNA vaccines (mRNA-1273 or BNT162b2), which significantly decreased after 6 months. In contrast, antibody levels were lower after Ad26.COV2.S vaccination but did not wane. Neutralization assays with infectious virus showed consistent cross-neutralization of the Beta and Delta variants, but neutralization of Omicron was significantly lower or absent (up to a 34-fold decrease compared to WT). Notably, BNT162b2 booster vaccination after either two mRNA-1273 immunizations or Ad26.COV.2 priming partially restored neutralization of the Omicron variant, but responses were still up to-17-fold decreased compared to WT. SARS-CoV-2-specific T-cells were detected up to 6 months after all vaccination regimens, with more consistent detection of specific CD4+ than CD8+ T-cells. No significant differences were detected between WT- and variant-specific CD4+ or CD8+ T-cell responses, including Omicron, indicating minimal escape at the T-cell level. This study shows that vaccinated individuals retain T-cell immunity to the SARS-CoV-2 Omicron variant, potentially balancing the lack of neutralizing antibodies in preventing or limiting severe COVID-19. Booster vaccinations are needed to further restore Omicron cross-neutralization by antibodies. Vaccination-induced SARS-CoV-2-specific CD4+ and CD8+ T-cells targeting the ancestral Spike protein cross-recognize the Omicron variant.
登录
查看更多内容
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
DOI：
10.1056/nejmoa2107659
发表时间：
2021-09-23
期刊：
The New England journal of medicine
影响因子：
--
作者：
Heath PT;Galiza EP;Baxter DN;Boffito M;Browne D;Burns F;Chadwick DR;Clark R;Cosgrove C;Galloway J;Goodman AL;Heer A;Higham A;Iyengar S;Jamal A;Jeanes C;Kalra PA;Kyriakidou C;McAuley DF;Meyrick A;Minassian AM;Minton J;Moore P;Munsoor I;Nicholls H;Osanlou O;Packham J;Pretswell CH;San Francisco Ramos A;Saralaya D;Sheridan RP;Smith R;Soiza RL;Swift PA;Thomson EC;Turner J;Viljoen ME;Albert G;Cho I;Dubovsky F;Glenn G;Rivers J;Robertson A;Smith K;Toback S;2019nCoV-302 Study Group
通讯作者：
2019nCoV-302 Study Group
影响因子：
82.9
作者：
Gao Y;Cai C;Grifoni A;Müller TR;Niessl J;Olofsson A;Humbert M;Hansson L;Österborg A;Bergman P;Chen P;Olsson A;Sandberg JK;Weiskopf D;Price DA;Ljunggren HG;Karlsson AC;Sette A;Aleman S;Buggert M
通讯作者：
Buggert M
影响因子：
64.5
作者：
Hoffmann M;Krüger N;Schulz S;Cossmann A;Rocha C;Kempf A;Nehlmeier I;Graichen L;Moldenhauer AS;Winkler MS;Lier M;Dopfer-Jablonka A;Jäck HM;Behrens GMN;Pöhlmann S
通讯作者：
Pöhlmann S
影响因子：
56.9
作者：
Lamers, Mart M.;Beumer, Joep;Clevers, Hans
通讯作者：
Clevers, Hans